admeddicon.com Open in urlscan Pro
176.52.244.94  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content
 * Services
 * Profile
 * Regulatory Resources

 * Services
 * Profile
 * Regulatory Resources

Contact


EXPERT DMPK CONSULTING FOR STREAMLINED DRUG DISCOVERY AND DEVELOPMENT.

Contact

ADMEDDICON – DMPK Consulting is an independent preclinical consulting firm
supporting biotech start-ups, university spin-offs and venture capitalists in
bringing their assets from discovery into clinical stage development.





PARTNERING WITH YOU TO OVERCOME THE CHALLENGES OF DRUG DEVELOPMENT

Drug discovery without considering monetary constraints is already a challenge.
When funding is limited, the definition of key questions, smart experimental
design, and, if relevant, consideration of regulatory frameworks become critical
aspects in achieving the next project milestone in a scientifically sound and
cost-efficient manner.

During the past 25 years in Swiss pharma and biotech companies, I have helped
bringing more than 50 drug candidates from lead discovery to clinical stage
development, eight of which finally received marketing authorization and improve
patients´ quality of life. ADMEDDICON thus has the expertise to support your
projects with its proven scientific excellence, cost consciousness and
regulatory experience.

The range of ADMEDDICON services covers all aspects of pharmacokinetic
optimization and characterization, ranging from early lead profiling to
candidate selection, PK/PD correlations, formulation strategies for pharmacology
and toxicology programs, first-in-human packages including toxicokinetics,
drug-drug interaction strategies from in vitro data to clinical trials,
metabolite safety assessments, and scientific consultancy for human ADME
studies.

For questions outside its core competence, ADMEDDICON works with a network of
qualified experts in the field of toxicology, regulatory, CMC, research
informatics and early clinical development.

I am a strong believer in interdisciplinary science and a lover of jazz music.
Discovering drugs in fact has a lot in common with making music. It needs
talented individuals that master their own instruments, but all equally need to
listen to the sound of their neighbors.




SERVICES




STRATEGIC CONSULTING

 * DMPK strategies for lead optimization
 * DMPK strategies for and beyond IND-enabling programs
 * Drug-drug interaction strategies (from test tube to clinical trial)
 * Strategic positioning for in- and outlicensing opportunities


SCIENTIFIC CONSULTING

 * Design of lead optimization programs
 * DMPK trouble-shooting
 * PK/PD analyses
 * Bioanalytics
 * Formulation strategies for pharmacology and toxicology
 * Toxicokinetics
 * Human ADME studies


OPERATIONAL CONSULTING

 * DMPK project management
 * CRO selection
 * External study monitoring
 * Interim management


REGULATORY WRITING

 * Investigator´s Brochures
 * Investigational New Drug Applications
 * Scientific Advice Briefing Books
 * Regulatory Filings (US FDA, EMA, PMDA)


PROFILE

I am an organic chemist by education but gradually moved away from synthetic
chemistry during my PhD thesis looking into mechanisms of natural DNA damage and
thus the molecular origin of evolution. As a postdoc, I worked on the metabolic
activation of thiophene-containing drugs and their toxicity to the liver. This
work opened the door to pharmaceutical industry which had just recognized the
value of integrating pharmacokinetic and toxicological optimization early into
the drug discovery process.

After four years at F. Hoffmann-La Roche AG in Basel as a drug metabolism
scientist, I joined the newly created Actelion Pharmaceuticals Ltd to build a
DMPK organization covering the entire process from lead optimization up to
regulatory filing. In 2017, Actelion was acquired by Johnson & Johnson for 30
billion USD, and the research and early development units were transferred into
a new company, Idorsia Pharmaceuticals Ltd. I was part of its research
management team and thus co-responsible for the strategic, scientific and
organizational management of a 35-project pipeline.


Early in 2024, I founded ADMEDDICON – DMPK Consulting, an independent
preclinical consulting firm with the idea to share my strategic and scientific
experience in collaborations with biotech companies, university spin-offs and
venture capital firms.


Previous Positions Education Publications

1996-2000

Laboratory Head, Preclinical Drug Metabolism, F. Hoffmann – La Roche AG, Basel

2000-2004
Director, Head Nonclinical DMPK, Actelion Pharmaceuticals Ltd, Allschwil

2004-2009

Senior Director, Head Nonclinical DMPK, Actelion Pharmaceuticals Ltd

2009-2017

Vice President, Head Nonclinical DMPK, Actelion Pharmaceuticals Ltd
2017-2023
Vice President, Head Nonclinical DMPK, Idorsia Pharmaceuticals Ltd, Allschwil
2011-2023
Deputy Head Nonclinical Development, Actelion and Idorsia Pharmaceuticals Ltd
2024
Founder and Managing Director ADMEDDICON – DMPK Consulting

1984-1990

Chemistry studies at the universities of Heidelberg (Germany) and Bristol (UK).
Diploma thesis on rearrangement reactions of substituted triarylamines; awarded
with a grant of the Dr. Sophie-von-Bernthsen fond. Fellow of Studienstiftung des
Deutschen Volkes and Deutscher Akademischer Austauschdienst.
1996-2000
University of Würzburg, Germany, PhD thesis on mechanisms of DNA damage by
natural peroxides.

1995-1996

Centre National de la Recherche Scientifique, Paris, France, Postdoctoral stage
on drug-induced liver toxicity of thiophene-containing drugs. Fellow of the
Deutsche Forschungsgemeinschaft.
 1. Treiber, S. Seeland, B. Hashimi, J. Williams, H. Aissauoi. The metabolism of
    the selective orexin 1 receptor antagonist nivasorexant. Xenobiotica, 2024,
    54, 124-137. (Download PDF)

 2. Treiber, S. Seeland, J. Segrestaa, C. Lescop, M. H. Bolli. Reversible
    oxidation/reduction steps in the metabolic degradation of the glycerol side
    chain of the S1P1 agonist ponesimod. Xenobiotica, 2024, 54, 182-194.
    (Download PDF)

 3. A. Steiner, L. Botticelli, G. Bergamini, E. Micioni di Bonaventura, J.
    Gatfield, J. Williams, A. Treiber, C. Vaillant, C. Cifani, M. V. Micioni di
    Bonaventura. Evaluation of the selective orexin receptor antagonist
    nivasorexant in an animal model of binge eating disorder, J Eat Disorders,
    2024, doi: 10.1002/eat.24181. PMID: 38456603.

 4. T. Williams, M. H. Bolli, C. Brotschi, C. Roch, T. Sifferlen, M. A. Steiner,
    A. Treiber, J. Gatfield, C. Boss. Discovery of nivasorexant (ACT-539313):
    The first selective orexin-1-receptor antagonist (SO1RA) investigated in
    clinical trials. J. Med. Chem., 2024, 67, 344-354.

 5. Brotschi, M. H. Bolli, J. Gatfield, C. Roch, T. Sifferlen, A. Treiber, J. T.
    Williams, C. Boss. Pyrazole derivatives as selective orexin-2 antagonists
    (2-SORA): synthesis, structure-activity relationship, and sleep-promoting
    properties in rats. Royal Soc. Chem. Med Chem. J., 2024, 15, 334-354.

 6. Berger, P. Kaufmann, M. Berse, A. Treiber, N. Grignaschi, J. Dingemanse.
    Effect of nivasorexant (ACT‑539313), a selective orexin-1 receptor
    antagonist, on multiple cytochrome P450 probe substrates in vitro and in
    vivo using a cocktail approach in healthy subjects. Pharmacol. Res.
    Perspect., 2023, 11:201143, DOI:10.1002/prp2.1143.

 7. Treiber, H. Aissaoui, S. Delahaye, S. Glutz, J. Grimont, C. Müller, S.
    Seeland, V. Siefken, C. Boss. CYP3A4 catalyzes the rearrangement of the dual
    orexin receptor antagonist daridorexant to 4-hydroxy piperidinol
    metabolites. Chem. Med. Chem., 2023, 18, e202300030,
    DOI:10.1002/cmdc.202300030. (Download PDF)

 8. Treiber, S. Delahaye A. Weigel, P. Aeänismaa, J. Gatfield, S. Seeland. The
    metabolism of the dual orexin receptor antagonist daridorexant. Xenobiotica,
    2023, 53, 173-183.

 9. Treiber and M. H. Bolli. The bile salt export pump BSEP, in The Medicinal
    Chemist’s Guide to Solving ADMET Challenges (ed. P. Schnider), Royal Society
    of Chemistry, 2021, chapter 8, 160-171.

 10. Boss, J. Gatfield, C. Brotschi, B. Heidmann, T. Sifferlen, M. von Raumer,
     G. Schmidt, J.T. Williams, A. Treiber, C. Roch. The quest for the best dual
     orexin receptor antagonist (daridorexant) for the treatment of insomnia
     disorders. Chem. Med. Chem., 2020, 15, 2286-2305.

 11. Treiber, S. Delahaye, S. Seeland, C. Gnerre. The endothelin receptor
     antagonist macitentan for the treatment of pulmonary arterial hypertension:
     a cross-species comparison of its cytochrome P450 induction pattern.
     Pharmacol. Res. Perspect, 2020, 00:e00619; https://doi.org/
     10.1002/prp2.619. (Download PDF)

 12. Brotschi, M.H. Bolli, J. Gatfield, B. Heidmann, F. Jenck, C. Roch, T.
     Sifferlen, A. Treiber, J. T. Williams, C. Boss. From oxadiazole to triazole
     analogues: optimization towards a dual orexin receptor antagonist with
     improved in vivo efficacy in dogs. Chem. Med. Chem, 2020, 15, 1-20.

 13. Brotschi, C. Roch, J. Gatfield, A. Treiber, J. T. Williams, T. Sifferlen,
     B. Heidmann, F. Jenck, M.H. Bolli, C. Boss. Oxadiazole derivatives as dual
     orexin receptor antagonists: synthesis, structure-activity relationship,
     and sleep-promoting properties in rat. Chem. Med. Chem, 2019, 14,
     1257-1270.

 14. Ichikawa, T. Yamada, A. Treiber, C. Gnerre, J. Segrestaa, S. Seeland, K.
     Nonaka. Cross-species comparison of the metabolism and excretion of
     selexipag. Xenobiotica, 2019, 49, 284-301.

 15. Ichikawa, T. Yamada, K. Nonaka, A. Treiber, C. Gnerre, K. Seya, S. Ochi.
     Pharmacokinetics of the selective prostacyclin receptor agonist selexipag
     in rats, dogs, and monkeys. Xenobiotica, 2018, 48, 186-196.

 16. Gnerre, J. Segrestaa, S. Seeland, P. Aeänismaa, T. Pfeifer, S. Delahaye, R.
     de Kanter, T. Ichikawa, T. Yamada, A. Treiber. The metabolism and drug-drug
     interaction potential of the selective prostacyclin receptor agonist
     selexipag. Xenobiotica, 2017, Aug 30, 1-16.

 17. Treiber, R. de Kanter, C. Roch, J. Gatfield, C. Boss, M. von Raumer, B.
     Schindelholz, C. Mühlan, J. van Gerven, F. Jenck. The use of PBPK modeling
     in the discovery of the dual orexin antagonist ACT-541468. J. Pharmacol.
     Exp. Ther., 2017, 362,489-503. (Download PDF)

 18. H. Bolli, C. Boss, A. Treiber, J. Gatfield. The discovery of macitentan – A
     standard medicinal discovery program? In: S. Chackalamannil, D. P. Rotella
     and S. E. Ward (eds.). Comprehensive Medicinal Chemistry III, 2017, vol. 8,
     252-283.

 19. Heidmann, J. Gatfield, C. Roch, A. Treiber, S. Tortoioli, C. Brotschi, J.
     T. Williams, M. H. Bolli, T. Sifferlen, F. Jenck, C. Boss. Discovery of
     highly potent dual orexin receptor antagonists via a scaffold hopping
     approach. Chem. Med. Chem, 2016, 11, 2132-2146.

 20. de Kanter, P. Sidharta, S. Delahaye, C. Gnerre, J. Segrestaa, S. Buchmann,
     C. Kohl, A. Treiber. Physiologically-based pharmacokinetic (PBPK) modeling
     of macitentan: prediction of drug-drug interactions. Clin. Pharmacokin.,
     2016, 55, 369-380.

 21. Caroff, F. Hubler, E. Meyer, D. Renneberg, A. Treiber, M. Rey, P. Hess, B.
     Steiner, K. Hilpert, M. A. Riederer.
     4-((R)-2-{[6-((S)-3-Methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic
     acid butyl ester (ACT‑246475), a novel P2Y12 receptor antagonist with an
     improved in vivo efficacy/safety ratio. J. Med. Chem., 2015, 58, 9133-9153.

 22. Treiber, T. Miraval, M. H. Bolli, J.-A. Funel, J. Segrestaa, S. Seeland.
     The metabolism of the dual endothelin receptor antagonist macitentan in the
     rat and dog. Xenobiotica., 2015, 4, 1-15.

 23. T. Williams, J. Gatfield, C. Roch, A. Treiber, F. Jenck, M. H. Bolli, T.
     Sifferlen, B. Heidmann, C. Boss. Discovery and optimization of 2-benzyl
     pyrrolidine carboxamides as potent dual orexin antagonists. Chem Med Comm,
     2015, 6, 1054-1064.

 24. Sifferlen, A. Boller, A. Chardonneau, E. Cottreel, J. Gatfield, A. Treiber,
     C. Roch, F. Jenck, H. Aissaoui, J. T. Williams, C. Brotschi, B. Heidmann,
     R. Siegrist and C. Boss. Substituted pyrrolidin-2ones: Centrally acting
     orexin receptor antagonist promoting sleep. Bioorg. Med. Chem. Lett., 2015,
     25, 1884-1891.

 25. N. Sidharta, A. Treiber, J. Dingemanse. Clinical pharmacokinetics and
     pharmacodynamics of the endothelin receptor antagonist macitentan: A
     systematic review. Clin. Pharmacokin. 2015, 54, 457-471.

 26. Seeland, H. Kettiger, M. Murphy, A. Treiber, J. Giller, A. Kiss, R. Sube,
     S. Krähenbühl, M. Hafner, J. Huwyler. ATP-induced cellular stress and
     mitochondrial toxicity in cells expressing purinergic P2X7 receptor.
     Pharmacol. Res. Perspectives, 2015, 3, e00123.

 27. Gehin, P. N. Sidharta, C. Gnerre, A. Treiber, A. Halabi, J. Dingemanse.
     Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2
     antagonist. Eur. J. Clin. Pharmacol., 2015, 71. 15-23.

 28. Boss, C. Roch-Brisbare, A. Treiber, M. A. Steiner, F. Jenck, M. von Raumer,
     T. Sifferlen, C. Brotschi, M. Bolli, B. Heidmann, J. Williams, H. Aissaoui,
     R. Siegrist and J. Gatfield. Structure-activity relationship, biological
     and pharmacological characterization of the proline sulfonamide ACT-462206,
     a highly potent, brain-penetrant dual orexin 1/ orexin 2 receptor
     antagonist. Chem Med Chem, 2014, 9. 2486-2496.

 29. Caroff, E. Meyer, A. Treiber, K. Hilpert, M. Riederer. Optimization of
     2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable, and
     selective P2Y12 antagonists for inhibition of platelet aggregation.
     Bioorganic & Medicinal Chemistry Letters 2014, 24, 4323-4331.

 30. Treiber, P. Aänismaa, R. de Kanter, S. Delahaye, M. Treher, P. Hess, P.
     Sidharta. Macitentan does not interfere with hepatic bile salt transport.
     J. Pharm. Exp. Ther. 2014, 350, 130-143. (Download PDF)

 31. Sifferlen, A. Boller, A. Chardonneau, E. Cottreel, J. Höcker, H. Aissoui,
     J. T. Williams, B. Heidmann, R. Siegrist, T. Weller, J. Gatfield, A.
     Treiber, C. Brisbare-Roch, F. Jenck, C. Boss. Discovery of substituted
     lactams as novel, dual orexin receptor antagonists. Synthesis, preliminary
     structure activity relationship studies and efforts towards improved
     metabolic stability and pharmacokinetic properties. Part I. Bioorg. Med.
     Chem. Lett., 2014, 24, 1201-1208.

 32. H. Bolli, C. Müller, B. Mathys, S. Abele, M. Birker, R. Bravo, D. Bur, C.
     Kohl, D. Lehmann, O. Nayler, M. Rey, S. Meyer, M. Scherz, G. Schmidt, B.
     Steiner, A. Treiber, J. Velker, T. Weller. Novel S1P1 receptor agonists –
     Part 1: From pyrazoles to thiophenes. J. Med. Chem.2013, 56, 9737-9755.

 33. A. Steiner, J. Gatfield, C. Brisbare-Roch, H. Dietrich, F. Jenck, A.
     Treiber, F. Jenck, C. Boss. Discovery and characterization of ACT-335827,
     an orally available, brain-penetrant orexin receptor type-1 selective
     antagonist. J. Med. Chem., 2013, 8, 898-903.

 34. Seeland, M. Török, H. Kettiger, A. Treiber, M. Hafner, J. Huwyler. A
     cell-based, multi-parametric sensor approach characterises drug-induced
     cytotoxicity in human liver HepG2 cells. Toxicology in vitro 2013, 27,
     1109-1120.

 35. Dingemanse, A. Treiber, K. Shakeri-Nejad, G. Hopfgartner, P. Hoever.
     Elucidation of the metabolic pathways and the resulting multiple
     metabolites of almorexant, a dual orexin receptor antagonist, in humans.
     Drug Metab. Dispos. 2013, 41, 1046-1059.

 36. Fahrmayr, J. König, D. Auge, M. Mieth, J. Segrestaa, T. Pfeifer, A.
     Treiber, M. F. Fromm. Phase I and II metabolism and MRP2-mediated export of
     bosentan in a MDCKII-OATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell
     line. Br. J. Pharmacol. 2013, 169, 21-33.

 37. H. Bolli, C. Boss, C. Binkert, S. Buchmann. D. Bur, P. Hess, M. Iglarz, S.
     Meyer, J. Rein, M. Rey, A. Treiber, M. Clozel, W. Fischli, T. Weller. The
     discovery of
     N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide
     (macitentan), an orally active, potent dual endothelin receptor antagonist.
     J. Med. Chem. 2012, 55, 7849-7861.

 38. Bruderer, G. Hopfgartner, M. Seiberling, J. Wank, A. Treiber, J.
     Dingemanse. Absorption, distribution, metabolism, and excretion of
     macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica,
     2012, 14, 901-910.

 39. Bruderer, P. Aeänismaa, M.C. Homery, S. Häusler, K. Landskroner, P.
     Sidharta, A. Treiber, J. Dingemanse. Effect of cyclosporine A and
     rifampicin on the pharmacokinetics of macitentan, a tissue-targeting
     endothelin receptor antagonist. AAPS J. 2012, 68-78.

 40. Seeland, A. Treiber, M. Hafner, J. Huwyler. On-line identification of
     P-glycoprotein substrates by monitoring of extracellular acidification and
     respiration rates in living cells. Biochim. Biophys. Acta – Biomembranes
     2011, 1808, 1827-1831.

 41. Landskroner, P. Hess, A. Treiber. Surgical and pharmacological animal
     models used in drug metabolism and pharmacokinetics, Xenobiotica 2011, 48,
     687-700.

 42. Corminboeuf, O. Bezencon, L. Remen, C. Grisostomi, S. Richard-Bildstein, D.
     Bur, L Prade, P. Strickner, P. Hess, W. Fischli, B. Steiner, A. Treiber.
     Piperidine-based renin inhibitors: upper chain optimization. Bioorg. Med.
     Chem. Lett. 2010, 20, 6291-6296.

 43. Corminboeuf, O. Bezencon, C. Grisostomi, L. Remen, S. Richard-Bildstein, D.
     Bur, L Prade, P. Hess, P. Strickner, W. Fischli, B. Steiner, A. Treiber.
     Design and optimization of new piperidines as renin inhibitors. Bioorg.
     Med. Chem. Lett. 2010, 20, 6286-6290.

 44. H. Bolli, S. Abele, C. Binkert, R. Bravo, S. Buchmann, D. Bur, J. Gatfield,
     P. Hess, C. Kohl, C. Mangold, B. Mathys, K. Menyhart, C. Müller, O. Nayler,
     M. Scherz, G. Schmidt, V. Sippel, B. Steiner, D. Strasser, A. Treiber, T.
     Weller. 2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1
     receptor agonists. J. Med. Chem. 2010, 53, 4198–4211

 45. Remen, O. Bezençon, S. Richard-Bildstein, D. Bur, L. Prade, O. Corminboeuf,
     C. Boss, C. Grisostomi, T. Sifferlen, P. Strickner, P. Hess, S. Delahaye,
     A. Treiber, T. Weller, C. Binkert, B. Steiner, W. Fischli. New classes of
     potent and bioavailable human renin inhibitors. Bioorg. Med. Chem. Lett.,
     2009, 19, 6762-6765.

 46. Bezençon, D. Bur, T. Weller, S. Richard-Bildstein, L. Remen, T. Sifferlen,
     O. Corminboeuf, C. Grisostomi, L. Prade, S. Delahaye, A. Treiber, P.
     Strickner, P. Hess, B. Steiner, and W. Fischli. Design and preparation of
     potent, non-peptidic, bioavailable renin inhibitors. J. Med. Chem., 2009,
     52, 3689-3702.

 47. L.M. van Giersbergen, A. Treiber, J. Dingemanse. In vitro and in vivo
     pharmacokinetic characteristics of clazosentan, an intravenous endothelin
     receptor antagonist, in humans, Int. J. Clin. Pharm. Ther. 2009, 47,
     169-177.

 48. Aissaoui, R. Koberstein, C. Zumbrunn, J. Gatfield, C. Brisbare-Roch, F.
     Jenck, A. Treiber, C. Boss. N-Glycine-sulfonamides as potent dual
     orexin-1/orexin-2 receptor antagonists. Bioorg. Me.l Chem. Lett. 2008, 18,
     5729-5733.

 49. Iglarz, C. Binkert, K. Morrison, W. Fischli, J. Gatfield, A. Treiber, T.
     Weller, M.H. Bolli, C. Boss, S. Buchmann, B. Capeleto, P. Hess, C. Qiu, M.
     Clozel. Pharmacology of macitentan, an orally active, tissue-targeting dual
     endothelin receptor antagonist. J. Pharm. Exp. Ther. 2008, 327, 736-745.

 50. Treiber, O. Morand, M. Clozel. The pharmacokinetics and tissue distribution
     of miglustat in the rat, Xenobiotica 2007, 37, 298-314.

 51. Treiber, R. Schneiter, S. Häussler, B. Stieger. Bosentan is a substrate of
     human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common
     mechanism of its interactions with cyclosporin A, rifampicin and
     sildenafil, Drug Metab. Dispos. 2007, 35, 1400-1408. (Download PDF)

 52. L.M. van Giersbergen, A. Treiber, R. Schneiter, H. Dietrich, J. Dingemanse.
     Inhibitory and inductive effects of rifampicin on the pharmacokinetics of
     bosentan in healthy subjects, Clin. Pharm. Ther. 2007, 81, 414-419.

 53. H. Bolli, J. Marfurth, C. Grisostomi, C. Boss, C. Binkert, P. Hess, A.
     Treiber, E. Thorin, K. Morrison, S. Buchmann, D. Bur, H. Ramuz, M. Clozel,
     W. Fischli, T. Weller. Novel benzo-(1,4)-diazepin-2-one derivatives as
     endothelin receptor antagonists. J. Med. Chem. 2004, 47, 2776-2795

 54. Treiber, R. Schneiter, S. Delahaye, M. Clozel. Inhibition of organic anion
     transporting polypeptide-mediated hepatic uptake is the major determinant
     in the pharmacokinetic interaction between bosentan and cyclosporin A in
     the rat. J. Pharm. Exp. Ther. 2004, 308, 1121-1129.

 55. Koberstein, H. Aissaoui, D. Bur, M. Clozel, W. Fischli, F. Jenck, C.
     Müller, O. Nayler, T. Sifferlen, A. Treiber, T. Weller.
     Tetrahydroisoquinolines as orexin receptor antagonists: strategies for lead
     optimization by solution-phase chemistry. Chimia 2003, 57, 270-275.

 56. Treiber, P.L.M. van Giersbergen, J. Dingemanse. In vivo and in vitro
     disposition profile of tezosentan, an intravenous dual endothelin receptor
     antagonist, in humans. Xenobiotica 2003, 33, 399-414.

 57. Rasmussen, P.H. Poulsen, A. Treiber, S. Delahaye, A. Tankisi, G.E. Cold, K.
     Therkelsen, A. Gjedde, J. Astrup. No influence of the endothelin receptor
     antagonist bosentan on basal and indomethacin-induced reduction of cerebral
     blood flow in pigs. Acta Anaesthesiol. Scand., 2003, 47 (2), 200-207.

 58. L.M. van Giersbergen, C. Gnerre, A. Treiber, J. Dingemanse, U.A. Meyer.
     Bosentan, a dual endothelin receptor antagonist, activates the pregnane X
     nuclear receptor. Eur. J. Pharmacol. 2002, 450 (2), 115-121.

 59. Treiber, P.M. Dansette, D. Mansuy. Mechanism of the aromatic hydroxylation
     of thiophene by acid-catalyzed peracid oxidation. J. Org. Chem. 2002, 67,
     7261-7266.

 60. L.M. van Giersbergen, A. Treiber, M. Clozel, F. Bodin, J. Dingemanse. In
     vitro and in vivo studies exploring the pharmacokinetic interaction between
     bosentan, a dual endothelin receptor antagonist, and glyburide. Clin.
     Pharmacol. Ther. 2002, 71, 253-262.

 61. P. Märki, …, A. Treiber, … Piperidine renin inhibitors: from leads to drug
     candidates. Farmaco 2001, 56, 21-27.

 62. T. Ho, A. Treiber, D. Mansuy, P.M. Dansette. Oxidation of
     2-(4-chlorobenzoyl)-thiophene into 1-oxide Diels-Alder dimers, sesquioxide
     and a sulfone-water adduct. Tetrahedron Letters 1998, 39, 5049-5052.

 63. Treiber, P.M. Dansette, H. El Hamri, D. Ginderow, J. P. Mornon, D. Mansuy.
     Preparation and complete characterization of thiophene-S-oxide dimers from
     chemical and biological oxidation of thiophene: evidence for intermediate
     formation of thiophene-S-oxide in thiophene metabolism in vivo and in
     vitro. J. Am. Chem. Soc. 1997, 119, 1565-1571.

 64. Adam, R. Stössel, A. Treiber. The SN2-reactivity of 3,3-disubstituted
     1,2-dioxetanes with morpholine. J. Org. Chem. 1995, 60, 2879-2884.

 65. Adam, A. Treiber. Oxidation of acetylated guanosine by 3,3-disubstituted
     1,2-dioxetanes through nucleophilic attack on the peroxide bond: model
     studies on the oxidative DNA damage by reactive peroxides. J. Am. Chem.
     Soc. 1995, 117, 2686-2693.

 66. Adam, L. Hadjiarapoglou, K. Mielke, A. Treiber. Competitive epoxidation and
     quinone formation in the dimethyldioxirane oxidation of diazoquinones as
     ambident nucleophiles. Tetrahedron Letters 1994, 35, 5625-5628.

 67. Adam, H. M. Harrer, A. Treiber. Synthesis of 1,4-dioxa-2l5-phosphorinanes
     by insertion of triphenylalkylidene phosphoranes into the peroxide bond of
     1,2-dioxetanes: thermolysis, hydrolysis and Wittig olefination. J. Am.
     Chem. Soc. 1994, 116, 7581-7587.

 68. Adam, A. Treiber. 1,3-Dioxolane formation by nucleophilic attack of
     diazoalkanes on the peroxide bond of 1,2-dioxetanes. J. Org. Chem.1994, 59,
     840-844.

 





REGULATORY RESOURCES




ICH

Non-clinical safety studies for the conduct of human trials: ICH M3 (R2)

Drug-drug interactions: ICH M12

Bioanalytical method development: ICH M10

Toxicokinetics: ICH S3A

Non-clinical evaluation of anticancer drugs: ICH S9


FDA

Safety testing of drug metabolites: MIST guideline

Human ADME studies

Human starting dose

Drug-induced liver injury

PBPK modelling


EMA

First-in-man clinical trials

PBPK modelling

Pharmacogenomics


GET IN TOUCH

ADMEDDICON – DMPK Consulting
Leinhaldenweg 4
79104 Freiburg
Germany
Founder and Managing Director
Dr. Alexander Treiber

Legal Disclosure

Data policy

Linkedin
 * contact@admeddicon.com
 * +49 152 02024765
 * +41 79 8244918

© Copyright 2024 ADMEDDICON – DMPK Consulting Dr. Alexander Treiber | Design &
Web Development by Schleiner + Partner Kommunikation GmbH

Privacy Preference

We need your consent before you can continue on our website. If you are under 16
and wish to give consent to optional services, you must ask your legal guardians
for permission. We use cookies and other technologies on our website. Some of
them are essential, while others help us to improve this website and your
experience. Personal data may be processed (e.g. IP addresses), for example for
personalized ads and content or ad and content measurement. You can find more
information about the use of your data in our privacy policy. You can revoke or
adjust your selection at any time under Settings.

Privacy Preference
 * Essential
   
   Essential cookies enable basic functions and are necessary for the proper
   function of the website.

 * Statistics
   
   Statistics cookies collect information anonymously. This information helps us
   to understand how our visitors use our website.

Accept all

Save

Accept only essential cookies

Individual Privacy Preferences

Cookie Details
Privacy Preference

If you are under 16 and wish to give consent to optional services, you must ask
your legal guardians for permission. We use cookies and other technologies on
our website. Some of them are essential, while others help us to improve this
website and your experience. Personal data may be processed (e.g. IP addresses),
for example for personalized ads and content or ad and content measurement. You
can find more information about the use of your data in our privacy policy. Here
you will find an overview of all cookies used. You can give your consent to
whole categories or display further information and select certain cookies.

Accept all Save Accept only essential cookies

Back

Privacy Preference
Essential (1)


Essential cookies enable basic functions and are necessary for the proper
function of the website.

Show Cookie Information Hide Cookie Information

Name Borlabs Cookie Provider Owner of this website Purpose Saves the visitors
preferences selected in the Cookie Box of Borlabs Cookie. Cookie Name
borlabs-cookie Cookie Expiry 1 Year

Statistics (1)
Statistics

Statistics cookies collect information anonymously. This information helps us to
understand how our visitors use our website.

Show Cookie Information Hide Cookie Information

Accept Google Analytics Name Google Analytics Provider Google Ireland Limited,
Gordon House, Barrow Street, Dublin 4, Ireland Purpose Cookie by Google used for
website analytics. Generates statistical data on how the visitor uses the
website. Privacy Policy https://policies.google.com/privacy?hl=en Cookie Name
_ga,_gat,_gid Cookie Expiry 2 Months

powered by Borlabs Cookie